187 related articles for article (PubMed ID: 29683931)
21. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
22. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
23. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
[TBL] [Abstract][Full Text] [Related]
24. [Clinical application of (18)F-FDG PET/CT to staging and treatment effectiveness monitoring of nasopharyngeal carcinoma].
Wang GH; Lau EW; Shakher R; Binns DS; Hogg A; Drummond E; Hicks RJ
Ai Zheng; 2007 Jun; 26(6):638-42. PubMed ID: 17562272
[TBL] [Abstract][Full Text] [Related]
25. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
[TBL] [Abstract][Full Text] [Related]
26. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
27. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
[TBL] [Abstract][Full Text] [Related]
28. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
30. Urinary bladder leiomyosarcoma: staging with 18F-FDG PET/CT.
Makis W; Rakheja R; Nahal A; Hickeson M; Lisbona R
Clin Nucl Med; 2013 May; 38(5):e218-22. PubMed ID: 23377410
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
32. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas.
Piperkova E; Mikhaeil M; Mousavi A; Libes R; Viejo-Rullan F; Lin H; Rosen G; Abdel-Dayem H
Clin Nucl Med; 2009 Mar; 34(3):146-50. PubMed ID: 19352275
[TBL] [Abstract][Full Text] [Related]
33. Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial.
Liu FY; Lai CH; Yang LY; Wang CC; Lin G; Chang CJ; Chang WY; Huang SH; Huang YE; Peng NJ; Hong JH; Chao A; Chou HH; Chang YC; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1812-23. PubMed ID: 27160224
[TBL] [Abstract][Full Text] [Related]
34. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
[TBL] [Abstract][Full Text] [Related]
35. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
36. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.
George A; Girault S; Testard A; Delva R; Soulié P; Couturier OF; Morel O
Nucl Med Commun; 2014 Mar; 35(3):282-90. PubMed ID: 24240193
[TBL] [Abstract][Full Text] [Related]
37. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
38. Metabolic assessment of Merkel cell carcinoma: the role of 18F-FDG PET/CT.
Ben-Haim S; Garkaby J; Primashvili N; Goshen E; Shapira R; Davidson T; Israel O; Epelbaum R
Nucl Med Commun; 2016 Aug; 37(8):865-73. PubMed ID: 27092665
[TBL] [Abstract][Full Text] [Related]
39. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET Assessment of Other Gynecologic Cancers.
Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]